Lara J Hererro1, Paul Griffin2, Ravi Krishnan3, Melanie Duiker3, Penny A Rudd1, Donna Skerrett3, James G D Pollard4, Carolyn Siddel5, Rifat Rifat6, Jennifer H K Ng7, Peter Georgius8. 1. Institute for Glycomics, Griffith University, Southport, Queensland, Australia. 2. Department of Medicine and Infectious Diseases, Mater Misericordiae Ltd., Level 3, Aubigny Place, Raymond Terrace, South Brisbane, Queensland, 4101, Australia. paul.griffin@mater.org.au. 3. Paradigm Biopharmaceuticals Ltd., Melbourne, Victoria, Australia. 4. Clinical Trials Unit, Barwon Health, Geelong, Victoria, Australia. 5. Springs Medical, Daylesford, Victoria, Australia. 6. Rich River Health Group, Echuca, Victoria, Australia. 7. Clinical Trials Unit (Griffith Health), Griffith University, Gold Coast, Australia and Gold Coast University, Gold Coast, Queensland, Australia. 8. Sunshine Coast Clinical Research, Gold Coast, Queensland, Australia.
Abstract
BACKGROUND:Alphaviruses, such as Ross River (RRV) and chikungunya virus (CHIKV), cause significant global morbidity, with outbreaks of crippling joint inflammation and pain, leaving patients incapacitated for months to years. With no available vaccine or specific therapeutic for any alphaviral disease, and a growing economic and public health burden, there is a serious need for the development of specific therapies. METHODS: This study evaluated the safety and efficacy of pentosan polysulfate sodium (PPS) in subjects with RRV-induced arthralgia in a double-blind, placebo-controlled trial. Twenty subjects were randomized 2:1 to subcutaneous PPS (2 mg/kg) or placebo (sodium chloride 0.9%) twice weekly for 6 weeks. Safety evaluation included physical examination, concomitant medications, and laboratory findings. Efficacy assessments included change from baseline in joint function (hand grip strength and RAPID3) and quality of life (SF-36) at Days 15, 29, 39 and 81 after treatment initiation. Inflammatory and cartilage degradation biomarkers were exploratory endpoints. RESULTS: PPS was well tolerated, with a similar proportion of subjects reporting at least one treatment-emergent adverse event (TEAE) in the treatment and placebo groups. Injection site reactions were the most common TEAE and occurred more frequently in the PPS group. Dominant hand grip strength and SF-36 scores improved with PPS at all time points assessed, with hand grip strength improvement of 6.99 kg (p = 0.0189) higher than placebo at Day 15. PPS showed significant improvements versus placebo in adjusted mean relative change from baseline for RAPID3 Pain (p = 0.0197) and Total (p = 0.0101) scores at Day 15. At the conclusion of the study overall joint symptoms, assessed by RAPID3, showed near remission in 61.5% of PPS subjects versus 14.3% of placebo subjects. Additionally, PPS treatment improved COMP, CTX-II, CCL1, CXCL12, CXCL16 and CCL17 biomarker levels versus placebo. CONCLUSIONS: Overall, the improvements in strength and joint symptoms warrant further evaluation of PPS as a specific treatment for RRV-induced and other forms of arthritis. TRIAL REGISTRATION: This trial is registered at the Australian New Zealand Clinical Trials Registry # ACTRN12617000893303 .
RCT Entities:
BACKGROUND: Alphaviruses, such as Ross River (RRV) and chikungunya virus (CHIKV), cause significant global morbidity, with outbreaks of crippling joint inflammation and pain, leaving patients incapacitated for months to years. With no available vaccine or specific therapeutic for any alphaviral disease, and a growing economic and public health burden, there is a serious need for the development of specific therapies. METHODS: This study evaluated the safety and efficacy of pentosan polysulfate sodium (PPS) in subjects with RRV-induced arthralgia in a double-blind, placebo-controlled trial. Twenty subjects were randomized 2:1 to subcutaneous PPS (2 mg/kg) or placebo (sodium chloride 0.9%) twice weekly for 6 weeks. Safety evaluation included physical examination, concomitant medications, and laboratory findings. Efficacy assessments included change from baseline in joint function (hand grip strength and RAPID3) and quality of life (SF-36) at Days 15, 29, 39 and 81 after treatment initiation. Inflammatory and cartilage degradation biomarkers were exploratory endpoints. RESULTS:PPS was well tolerated, with a similar proportion of subjects reporting at least one treatment-emergent adverse event (TEAE) in the treatment and placebo groups. Injection site reactions were the most common TEAE and occurred more frequently in the PPS group. Dominant hand grip strength and SF-36 scores improved with PPS at all time points assessed, with hand grip strength improvement of 6.99 kg (p = 0.0189) higher than placebo at Day 15. PPS showed significant improvements versus placebo in adjusted mean relative change from baseline for RAPID3 Pain (p = 0.0197) and Total (p = 0.0101) scores at Day 15. At the conclusion of the study overall joint symptoms, assessed by RAPID3, showed near remission in 61.5% of PPS subjects versus 14.3% of placebo subjects. Additionally, PPS treatment improved COMP, CTX-II, CCL1, CXCL12, CXCL16 and CCL17 biomarker levels versus placebo. CONCLUSIONS: Overall, the improvements in strength and joint symptoms warrant further evaluation of PPS as a specific treatment for RRV-induced and other forms of arthritis. TRIAL REGISTRATION: This trial is registered at the Australian New Zealand Clinical Trials Registry # ACTRN12617000893303 .
Entities:
Keywords:
Alphavirus; Arthritis; Pain; Pentosan polysulfate sodium; Ross River virus
Authors: Marianne Jensen Hjermstad; Peter M Fayers; Dagny F Haugen; Augusto Caraceni; Geoffrey W Hanks; Jon H Loge; Robin Fainsinger; Nina Aass; Stein Kaasa Journal: J Pain Symptom Manage Date: 2011-06 Impact factor: 3.612
Authors: N Charni-Ben Tabassi; S Desmarais; A-C Bay-Jensen; J M Delaissé; M D Percival; P Garnero Journal: Osteoarthritis Cartilage Date: 2008-04-09 Impact factor: 6.576
Authors: Kuniaki Ota; Patrick Quint; Megan M Weivoda; Ming Ruan; Larry Pederson; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler Journal: Bone Date: 2013-07-25 Impact factor: 4.398
Authors: Weiqiang Chen; Suan-Sin Foo; Nestor E Rulli; Adam Taylor; Kuo-Ching Sheng; Lara J Herrero; Belinda L Herring; Brett A Lidbury; Rachel W Li; Nicole C Walsh; Natalie A Sims; Paul N Smith; Suresh Mahalingam Journal: Proc Natl Acad Sci U S A Date: 2014-04-14 Impact factor: 11.205
Authors: Catherine J M Stapledon; Helen Tsangari; Lucian B Solomon; David G Campbell; Plinio Hurtado; Ravi Krishnan; Gerald J Atkins Journal: PLoS One Date: 2019-09-26 Impact factor: 3.240
Authors: Kothila Tharmarajah; Arun Everest-Dass; Jelena Vider; Xiang Liu; Joseph R Freitas; Helen Mostafavi; Jayaram Bettadapura; Mark von Itzstein; Nicholas P West; Adam Taylor; Suresh Mahalingam; Ali Zaid Journal: J Virol Date: 2022-08-24 Impact factor: 6.549
Authors: Helen Mostafavi; Kothila Tharmarajah; Jelena Vider; Nicholas P West; Joseph R Freitas; Barbara Cameron; Paul S Foster; Linda P Hueston; Andrew R Lloyd; Suresh Mahalingam; Ali Zaid Journal: PLoS Pathog Date: 2022-02-10 Impact factor: 6.823